Clinical Research and Prognosis of HER2-Positive Breast Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 28 February 2026 | Viewed by 530
Special Issue Editor
Special Issue Information
Dear Colleagues,
HER2-positive breast cancer, characterized by aggressive tumor behavior, has seen transformative advances with anti-HER2 therapies, significantly improving patient outcomes. This review highlights the long-term impacts of targeted treatments, including trastuzumab, pertuzumab, and antibody–drug conjugates like T-DM1. While these therapies markedly enhance survival rates and reduce recurrence, long-term follow-up reveals challenges such as cardiotoxicity, resistance mechanisms, and late-onset side-effects. Emerging strategies, including dual HER2 blockade and novel agents like trastuzumab deruxtecan, show promise in overcoming resistance. Prognostic biomarkers and personalized approaches are critical to optimizing long-term efficacy. Overall, anti-HER2 therapies have revolutionized care, but ongoing research is essential to address persistent limitations and improve lifelong outcomes for patients.
All submissions will undergo a rigorous peer-review process to ensure scientific rigor and relevance to the field. We invite contributions from researchers, clinicians, and experts in the domain of breast cancer research and treatment.
Should you have any inquiries, require additional information, or need assistance, please do not hesitate to contact us. We are dedicated to supporting your involvement in this Special Issue.
Thank you for your attention, and we eagerly anticipate receiving your insightful submissions.
Prof. Dr. Pierfranco Conte
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HER2-positive breast cancer
- targeted therapy
- anti-HER2 therapy
- long-term impacts
- prognostic
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
